This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Di Modugno, F. Articles by Nisticò, P. Search for Related Content PubMed PubMed Citation Articles by Di Modugno, F. Articles by Nisticò, P.

Molecular Cloning of hMena (ENAH) and Its Splice Variant hMena^+11a: Epidermal Growth Factor Increases Their Expression and Stimulates hMena^+11a Phosphorylation in Breast Cancer Cell Lines

¹ Experimental Chemotherapy, and ² Laboratory of Immunology, Regina Elena Cancer Institute; ³ Molecular Biology and Pathology Institute, National Research Council; ⁴ Experimental Medicine and Pathology, University "La Sapienza," Rome, Italy; ⁵ Tumor Immunology and ⁶ Proteome Biochemistry, Dibit, San Raffaele Scientific Institute, Milan, Italy; ⁷ Medizinische Klinik II, Hamatologie-Onkologie, Krankenhaus Nordwest, Frankfurt, Germany; and ⁸ Department of Anatomy, Structural Biology and Analytical Imaging Facility, Albert Einstein College of Medicine, Bronx, New York

Requests for reprints: Paola Nisticò, Immunology Laboratory, Regina Elena Cancer Institute, via delle Messi d'Oro 156, 00158 Rome, Italy. Phone: 39-6-5266-2539; Fax: 39-6-5266-2600; E-mail: nistico{at}ifo.it.

hMena (ENAH), an actin regulatory protein involved in the control of cell motility and adhesion, is modulated during human breast carcinogenesis. In fact, whereas undetectable in normal mammary epithelium, hMena becomes overexpressed in high-risk benign lesions and primary and metastatic tumors. In vivo, hMena overexpression correlates with the HER-2⁺/ER^–/Ki67⁺ unfavorable prognostic phenotype. In vitro, neuregulin-1 up-regulates whereas Herceptin treatment down-modulates hMena expression, suggesting that it may couple tyrosine kinase receptor signaling to the actin cytoskeleton. Herein, we report the cloning of hMena and of a splice variant, hMena^+11a, which contains an additional exon corresponding to 21 amino acids located in the EVH2 domain, from a breast carcinoma cell line of epithelial phenotype. Whereas hMena overexpression consistently characterizes the transformed phenotype of tumor cells of different lineages, hMena^+11a isoform is concomitantly present only in epithelial tumor cell lines. In breast cancer cell lines, epidermal growth factor (EGF) treatment promotes concomitant up-regulation of hMena and hMena^+11a, resulting in an increase of the fraction of phosphorylated hMena^+11a isoform only. hMena^+11a overexpression and phosphorylation leads to increased p42/44 mitogen-activated protein kinase (MAPK) activation and cell proliferation as evidenced in hMena^+11a–transfected breast cancer cell lines. On the contrary, hMena knockdown induces reduction of p42/44 MAPK phosphorylation and of the proliferative response to EGF. The present data provide new insight into the relevance of actin cytoskeleton regulatory proteins and, in particular, of hMena isoforms in coupling multiple signaling pathways involved in breast cancer. [Cancer Res 2007;67(6):2657–65]

This article has been cited by other articles:

				M. S. Pino, M. Balsamo, F. Di Modugno, M. Mottolese, M. Alessio, E. Melucci, M. Milella, D. J. McConkey, U. Philippar, F. B. Gertler, et al. Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines Clin. Cancer Res., August 1, 2008; 14(15): 4943 - 4950. [Abstract] [Full Text] [PDF]